[go: up one dir, main page]

MX2017010159A - Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. - Google Patents

Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.

Info

Publication number
MX2017010159A
MX2017010159A MX2017010159A MX2017010159A MX2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A
Authority
MX
Mexico
Prior art keywords
costimulatory molecules
vector
expressing vaccine
expressing
cells
Prior art date
Application number
MX2017010159A
Other languages
English (en)
Other versions
MX384422B (es
Inventor
Fromm George
schreiber Taylor
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of MX2017010159A publication Critical patent/MX2017010159A/es
Publication of MX384422B publication Critical patent/MX384422B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)

Abstract

Se proporcionan aquí composiciones y métodos para expresar en conjunto una proteína de vacuna secretable (tal como gp96-Ig) y moléculas coestimuladoras de células T de un solo vector, entre otros. También se proporcionan materiales y métodos para usar la vacunación con gp96-Ig y coestimulación de células T para tratar una afección clínica (por ejemplo, cáncer) en un sujeto.
MX2017010159A 2015-02-06 2016-02-05 Vector que expresa conjuntamente vacunas y moléculas coestimuladoras MX384422B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113153P 2015-02-06 2015-02-06
US201562174942P 2015-06-12 2015-06-12
PCT/US2016/016682 WO2016127015A1 (en) 2015-02-06 2016-02-05 Vector co-expressing vaccine and costimulatory molecules

Publications (2)

Publication Number Publication Date
MX2017010159A true MX2017010159A (es) 2017-12-18
MX384422B MX384422B (es) 2025-03-14

Family

ID=56564722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010159A MX384422B (es) 2015-02-06 2016-02-05 Vector que expresa conjuntamente vacunas y moléculas coestimuladoras

Country Status (15)

Country Link
US (4) US10046047B2 (es)
EP (1) EP3253876B1 (es)
JP (1) JP6744318B2 (es)
KR (1) KR20170109582A (es)
CN (1) CN107208099B (es)
AU (1) AU2016215175B2 (es)
BR (1) BR112017016681A2 (es)
CA (1) CA2975191C (es)
DK (1) DK3253876T3 (es)
ES (1) ES2845727T3 (es)
IL (1) IL253423B (es)
MX (1) MX384422B (es)
RU (1) RU2714157C2 (es)
SG (1) SG11201705844SA (es)
WO (1) WO2016127015A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
AU2016240411A1 (en) * 2015-04-02 2017-10-12 Cancure Limited Agents and compositions for eliciting an immune response
IL303586B2 (en) 2015-10-01 2025-03-01 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP3515486A4 (en) * 2016-09-26 2020-05-20 Advantagene, Inc. METHOD FOR TREATING TIM-3 INCREASE
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2018157163A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
BR112019017713A2 (pt) * 2017-02-27 2020-04-07 Shattuck Labs Inc proteínas quiméricas à base de csf1r
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
WO2018187260A1 (en) * 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
KR20200092964A (ko) * 2017-11-27 2020-08-04 히트 바이오로직스, 인코퍼레이티드 Gp96-기반 암 치료법
JP2021505138A (ja) * 2017-12-04 2021-02-18 ヒート バイオロジクス，インコーポレイテッド 細胞に基づくワクチンの製造
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
CA3109349A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
MX2021002294A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
CN113164574A (zh) * 2018-10-01 2021-07-23 热生物制品有限公司 基于细胞的组合疗法
CN113286813A (zh) * 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
AU2020340372A1 (en) * 2019-08-30 2022-03-10 Pelican Therapeutics, Inc. Methods of treating cancer using TNFRSF25 antibodies
US20210283242A1 (en) * 2020-03-02 2021-09-16 Heat Biologics, Inc. Immune-mediated coronavirus treatments
CN118201636A (zh) * 2021-10-26 2024-06-14 萨摩亚商柏沛生医股份有限公司 抗癌症及感染性疾病的组合疗法
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5217891A (en) 1987-07-28 1993-06-08 Chiron Corporation DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides
CA1338778C (en) 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
AU649228B2 (en) 1989-07-28 1994-05-19 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Efficient directional genetic cloning system
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DE69126668T2 (de) 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
US5177942A (en) 1991-08-15 1993-01-12 The Toro Company Mower deck with improved belt drive arrangement
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
AU4024593A (en) 1992-04-14 1993-11-18 Abbott Laboratories Method of detecting tumors containing complexes of P53 and HSP70
WO1993023431A1 (en) 1992-05-14 1993-11-25 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
PL311036A1 (en) 1993-03-19 1996-01-22 Boehringer Ingelheim Int Method of obtaining an anticarcinogenic vaccine
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
WO1995004824A1 (en) 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Generation of dna libraries and retroviral vectors for same
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
CN1157560A (zh) 1994-07-08 1997-08-20 巴克斯特国际有限公司 用于治疗癌症的装载有肿瘤细胞的可植入装置
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
EP0784483B1 (en) 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
JPH11513369A (ja) 1995-09-13 1999-11-16 フォーダム ユニバーシティー 熱ショックタンパク質を用いる治療及び予防方法
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
AU734196B2 (en) 1996-03-28 2001-06-07 Whitehead Institute Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DE69735376T2 (de) 1996-11-26 2006-12-14 Stressgen Biotechnologies Corp., Victoria Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
DE69942810D1 (de) 1998-02-20 2010-11-11 Univ Miami Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP2332976B1 (en) * 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
CN1688695B (zh) * 2000-04-28 2011-05-11 约翰霍普金斯大学 新的树突状细胞共刺激分子
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
WO2003005964A2 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
EP1536829A4 (en) * 2001-08-20 2006-05-31 Univ Connecticut Health Ct METHOD FOR PRODUCING COMPOSITIONS WITH HEAT SHOCK PROTEINS OR ALPHA-2-MACROGLOBULIN FOR THE TREATMENT OF CANCER AND INFECTION DISEASES
ATE435655T1 (de) * 2001-10-09 2009-07-15 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
AU2002365275A1 (en) 2001-11-16 2003-07-09 Aventis Pasteur Novel chimeric rev, tat, and nef antigens
US7670781B2 (en) * 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US20030170756A1 (en) 2002-02-01 2003-09-11 Thomas Jefferson University Treatment of tumor cells for use in immunotherapy of cancer
CN1440812A (zh) * 2002-02-27 2003-09-10 上海中信国健药业有限公司 一种使用cd137结合激动剂增强免疫应答的方法
US20050221395A1 (en) * 2002-02-28 2005-10-06 Zabrecky James R Methods and products based on oligomerization of stress proteins
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
JP2006501147A (ja) * 2002-04-25 2006-01-12 ユニバーシティー オブ コネティカット ヘルス センター 非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
CN1756568A (zh) 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
EP1667701A4 (en) 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
JP4809227B2 (ja) 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
WO2005058950A2 (en) * 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
FR2867982B1 (fr) 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
US7592313B2 (en) * 2004-05-17 2009-09-22 Board Of Trustees Of The University Of Illinois Method of stimulating proliferation of regulatory T cells in a diabetic mammal
EP2243788A1 (en) 2005-02-24 2010-10-27 Medical Research Council HIVCON: An HIV immunogen and uses thereof
PT2650020T (pt) * 2005-05-06 2016-12-12 Providence Health & Services - Oregon Proteína de fusão de imunoglobulina ox-40 trimérica e métodos do campo de utilização
CA2621083C (en) * 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20100247562A1 (en) * 2006-08-24 2010-09-30 Trustees Of Boston University Complexes Derived from Heterohybrid Cells and Uses Thereof
EP2856876B1 (en) * 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ITPD20070252A1 (it) * 2007-07-24 2009-01-25 Primiero Paolo Complessi di grp94 ed immunoglobuline g umane
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
JP2011513399A (ja) 2008-03-03 2011-04-28 ザ ユニバーシティー オブ マイアミ 同種癌細胞による免疫療法
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
KR20110017356A (ko) * 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
AU2009316371B2 (en) 2008-11-21 2014-02-20 University Of Miami HIV/SIV vaccines for the generation of mucosal and systemic immunity
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2413953B1 (en) * 2009-04-03 2017-11-08 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
AU2010282340B2 (en) * 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
EP2482849B1 (en) * 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2794196A1 (en) * 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2011146395A2 (en) * 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
AU2011255463A1 (en) * 2010-05-21 2012-11-01 University Of Miami Cancer treatment
US9234042B2 (en) * 2010-10-18 2016-01-12 Delphi Genetics Sa Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
CN102462841A (zh) * 2010-11-09 2012-05-23 中国科学院微生物研究所 一种促进gp96蛋白的免疫活性的方法及其应用
CA2828443A1 (en) * 2011-02-23 2012-08-30 University Of Miami Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
CN109182266A (zh) * 2011-12-12 2019-01-11 细胞药物有限公司 扩大t细胞的方法
EP3466443B1 (en) * 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
JP2016500251A (ja) * 2012-12-03 2016-01-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強
AU2013371957B2 (en) * 2013-01-02 2018-10-25 Ichnos Sciences SA Antibodies that bind to TL1A and their uses
CA2897826C (en) * 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
US10196435B2 (en) * 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
EP3653714A1 (en) * 2013-11-22 2020-05-20 DNAtrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
JP6612252B2 (ja) * 2014-04-03 2019-11-27 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 腫瘍特異的免疫応答の有効性を増強するための方法
US9718870B2 (en) * 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
HK1250513A1 (zh) * 2015-05-07 2018-12-21 阿吉纳斯公司 抗ox40抗体及其使用方法
IL263406B2 (en) * 2016-06-09 2023-09-01 Pelican Therapeutics Inc Anti-tnfrs25 antibodies
WO2018187260A1 (en) * 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
KR20200092964A (ko) * 2017-11-27 2020-08-04 히트 바이오로직스, 인코퍼레이티드 Gp96-기반 암 치료법
CN113164574A (zh) * 2018-10-01 2021-07-23 热生物制品有限公司 基于细胞的组合疗法
US20220289838A1 (en) * 2019-08-19 2022-09-15 Nantong Yichen Biopharma. Co. Ltd. Immunocytokine, Preparation for the Same, and Uses Thereof
US20210283242A1 (en) * 2020-03-02 2021-09-16 Heat Biologics, Inc. Immune-mediated coronavirus treatments

Also Published As

Publication number Publication date
RU2017127025A3 (es) 2019-07-17
ES2845727T3 (es) 2021-07-27
RU2017127025A (ru) 2019-03-07
EP3253876B1 (en) 2020-11-04
EP3253876A4 (en) 2018-09-19
AU2016215175B2 (en) 2021-09-16
KR20170109582A (ko) 2017-09-29
US20180360955A1 (en) 2018-12-20
AU2016215175A1 (en) 2017-09-21
WO2016127015A1 (en) 2016-08-11
SG11201705844SA (en) 2017-08-30
CN107208099A (zh) 2017-09-26
US10780161B2 (en) 2020-09-22
MX384422B (es) 2025-03-14
CA2975191A1 (en) 2016-08-11
US10758611B2 (en) 2020-09-01
CA2975191C (en) 2023-05-09
US20210000945A1 (en) 2021-01-07
IL253423A0 (en) 2017-09-28
RU2714157C2 (ru) 2020-02-12
JP2018509888A (ja) 2018-04-12
EP3253876A1 (en) 2017-12-13
HK1247960A1 (zh) 2018-10-05
US20160250322A1 (en) 2016-09-01
BR112017016681A2 (pt) 2018-04-10
JP6744318B2 (ja) 2020-08-26
CN107208099B (zh) 2022-05-13
DK3253876T3 (da) 2021-01-25
IL253423B (en) 2021-08-31
US20190000967A1 (en) 2019-01-03
US10046047B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
MX2017010159A (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
CY1125196T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
UY38251A (es) Moléculas de unión contra bcma y usos de las mismas
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CL2016003324A1 (es) Construcciones de anticuerpos multiespecificos.
AR114031A2 (es) Moléculas de unión a 4-1bb
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
AR108516A1 (es) Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
MX2018007519A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
MX2018010616A (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
CO2018012513A2 (es) Anticuerpos
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
PE20151180A1 (es) Anticuerpos anti-ceacam5 y usos de estos
BR112015001543A2 (pt) camisa de refrigeração, camisa para uma camisa de refrigeração, meio de vedação para uma camisa de refrigeração, máquina elétrica e método para produzir uma camisa de refrigeração
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais